CLINICAL_TRIALS
trial_result
· 2018-10-03
Clinical Trial Update: A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting [Phase 3]
Summary
A pivotal Phase 3 trial evaluating HLD200 for attention deficit hyperactivity disorder in children has completed; results are posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ironshore Pharmaceuticals and Development, Inc | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2018-10-03